Affiliation: University of Miami
- Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosisAshok Verma
Department of Neurology, Kessenich Family MDA ALS Center, 1150 NW 14th Street, Suite 701, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
Muscle Nerve 34:235-7. 2006..No major adverse effects were noted. Local injection of a small dose of Botox into the parotid glands can control sialorrhea and potentially improve living quality in some patients with bulbar ALS...
- Primary lateral sclerosis with HIV-1 infectionAshok Verma
Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA
Neurology 70:575-7. 2008
- RNA quality control and protein aggregates in amyotrophic lateral sclerosis: a reviewAshok Verma
Department of Neurology, University of Miami Miller School of Medicine, Clinical Research Building, 1120 NW 14 Street, Suite 1317, Miami, Florida 33136, USA
Muscle Nerve 47:330-8. 2013..This article reviews the current research efforts toward understanding the role of RNA-processing regulation and protein aggregates in ALS...
- Protein aggregates and regional disease spread in ALS is reminiscent of prion-like pathogenesisAshok Verma
Department of Neurology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
Neurol India 61:107-10. 2013..This brief review discusses the prion-related domains in TDP-43 and FUS and their implication in protein aggregate formation and disease spread in ALS...
- Induced pluripotent stem cells and promises of neuroregenerative medicineAshok Verma
University of Miami Miller School of Medicine, Miami, FL, USA
Neurol India 59:555-7. 2011..This brief review summarizes currently available stem cell platforms, with emphasis on cellular reprogramming and iPS technology and its application in disease modeling and cell replacement therapy in neurodegenerative diseases...
- Epidemiology and clinical features of HIV-1 associated neuropathiesA Verma
Department of Neurology, University of Miami School of Medicine and Jackson Memorial Hospital, Florida, USA
J Peripher Nerv Syst 6:8-13. 2001..Because HIV-1-associated neuropathies are diverse in their etiology and pathogenesis, a precise clinical diagnosis is required to formulate a rational therapeutic intervention...
- Isolated cerebral mucormycosis: report of a case and review of the literatureAshok Verma
Department of Neurology, University of Miami School of Medicine, 1150 NW 14 Street, Suite 701, Miami, FL 33136, USA
J Neurol Sci 240:65-9. 2006..Early tissue diagnosis and the consequent surgical excision of the necrotic tissue and aggressive antifungal therapy might salvage life in this fatal condition...
- ALS syndrome in patients with HIV-1 infectionAshok Verma
Department of Neurology, Kessenich Family MDA ALS Center, University of Miami Miller School of Medicine, 1150 NW 14 Street, Suite 701, Miami, FL 33136, USA
J Neurol Sci 240:59-64. 2006..During the last 20 years, at least 19 cases of ALS or ALS-like disease have been reported in HIV-1 (HIV) seropositive individuals...
- Neuropathic scapuloperoneal syndrome (Davidenkow's syndrome) with chromosome 17p11.2 deletionAshok Verma
Department of Neurology, University of Miami Miller School of Medicine, Florida 33136, USA
Muscle Nerve 32:668-71. 2005..This observation suggests that the rare Davidenkow's syndrome is clinically related to HNPP and its genotype could be a chromosome 17p11.2 deletion...
- Opsoclonus-myoclonus syndrome following Epstein-Barr virus infectionAshok Verma
Department of Neurology, University of Miami School of Medicine, FL 33136, USA
Neurology 58:1131-2. 2002
- Bilateral basal ganglionic hemorrhageAshok Verma
Arch Neurol 63:464. 2006
- The ALS Nutrition/NIPPV Study: design, feasibility, and initial resultsEdward J Kasarskis
Department of Neurology, University of Kentucky, Lexington, Kentucky, USA
Amyotroph Lateral Scler 12:17-25. 2011..The results of this study will allow us to model equations to predict the energy requirements in ALS and to plan a study of early intervention with NIPPV...
- Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affectErik P Pioro
Section of ALS and Related Disorders, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Ann Neurol 68:693-702. 2010..To evaluate dextromethorphan combined with ultra low-dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS)...
- Amyotrophic lateral sclerosis: an emerging era of collaborative gene discoveryKatrina Gwinn
National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS ONE 2:e1254. 2007..This resource should facilitate genetic discoveries which we anticipate will ultimately provide a better understanding of the biological mechanisms of neurodegeneration in ALS...
- Recombinant tissue plasminogen activator in the treatment of intraventricular hemorrhage secondary to periventricular arteriovenous malformation before surgery: case reportKrishna Kumar
Department of Surgery, Section of Neurosurgery, Regina General Hospital, University of Saskatchewan, Regina, Saskatchewan, Canada
Neurosurgery 52:964-8; discussion 968-9. 2003....
- Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosisMerit E Cudkowicz
Neurology Clinical Trials Unit, Massachusetts General Hospital, 13th Street, Charlestown, MA 02129, USA
Muscle Nerve 38:837-44. 2008..Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned...
- Botulinum toxin type A therapy in a patient with cervical dystonia and amyotrophic lateral sclerosisCarlos Singer
Mov Disord 22:289. 2007